[1]
K.Miyano, K.; Manabe, S.; Komatsu, A.; Fujii, Y.; Mizobuchi, Y.; Uezono, E.; Ohshima, K.; Nonaka, M.; Kuroda, Y.; Narita, M.; Fujii, H.; Uezono, Y. The G protein signal-biased compound trv130; structures, its site of action and clinical studies. Curr. Top. Med. Chem., 2020, 20(31), 2822-2829.
[2]
Inagaki, M.; Kanemasa, T.; Yokota, T. Naldemedine: peripherally acting opioid receptor antagonist for treating opioid-induced adverse effects. Curr. Top. Med. Chem., 2020, 20(31), 2830-2842.
[3]
Fujita, W. Aiming at Ideal Therapeutics-MOPr/DOPr or MOPr-DOPr Heteromer-targeting ligand. Curr. Top. Med. Chem., 2020, 20(31), 2843-2851.
[4]
Bartuzi, D.; Wróbel, T.M.; Kaczor, A.A.; Matosiuk, D. Tuning down the pain – an overview of allosteric modulation of opioid receptors: mechanisms of modulation, allosteric sites, modulator syntheses. Curr. Top. Med. Chem., 2020, 20(31), 2852-2865.
[5]
Mizoguchi, H.; Fujii, H. Exploring μ-opioid receptor splice variants as a specific molecular target for new analgesics. Curr. Top. Med. Chem., 2020, 20(31), 2866-2877.
[6]
Kiguchi, N.; Ding, H.; Kishioka, S.; Ko, M-C. Nociceptin/orphanin fq peptide receptor-related ligands as novel analgesics. Curr. Top. Med. Chem., 2020, 20(31), 2878-2888.
[7]
Hirayama, S.; Fujii, H. δ opioid receptor inverse agonists and their in vivo pharmacological effects. Curr. Top. Med. Chem., 2020, 20(31), 2889-2902.
